Gene therapy deal dubbed a paradigm shift for bioengineering in India

19 June 2023

The Indian Institute of Technology Kanpur (IITK) has entered into a Memorandum of Agreement (MOA) with Laurus Labs (NSE: LAURUSLABS) to introduce gene therapy assets to the market.

This collaboration has been described as a ‘paradigm shift’ with regards to innovation and advancement in the field of bioengineering in India, as an unprecedented industry-first investment in a faculty research group.

According to the MOA, IIT Kanpur will transfer several gene therapy assets through in-licensing to Laurus Labs, which will provide a research grant to facilitate their progression through pre-clinical development.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK